Big Data for Better Outcomes, Policy Innovation and Healthcare System Transformation

DO->IT is the overall coordinator of the BD4BO activities within IMI and establishes the mechanisms for a sustainable focus on outcomes based healthcare delivery. DO->IT:

  • ensures quality, consistency and sustainability of health outcomes across BD4BO projects
  • integrates, synthesises, as well as is responsible for managing knowledge from BD4BO projects for easy access (knowledge exchange platform)
  • is a point of collaboration, stakeholder engagement and communication for BD4BO projects
  • additionally develops minimum data privacy standards for Informed Consent Forms (ICFs).

Partners:

  • London School of Economics and Political Science
  • Novartis
  • National Institute for Health and Care Excellence
  • Dental and Pharmaceutical Benefits Agency
  • European Cancer Patient Coalition
  • European Multiple Sclerosis Platform
  • Semmelweis University
  • Imperial College London
  • Swedi
  • sh Institute for Health Economics
  • Centre for Research in Healthcare Management– Università Bocconi
  • Norwegian Institute of Public Health
  • The Association of the British Pharmaceutical Industry
  • Amgen
  • Bayer
  • Boehringer Ingelheim
  • Celgene
  • European Federation of Pharmaceutical Industries and Associations
  • Farmaindustria
  • GlaxoSmithKline
  • Health iQ
  • InterSystems
  • Janssen Pharmaceutica NV
  • Eli Lilly and Company
  • Merck Group
  • MSD Sharp & Dohme
  • Novo Nordisk
  • Pfizer
  • Roche
  • Sanofi
  • Servier
  • UCB
  • Association of Research-Based Pharmaceutical Companies
  • Norwegian Medicines Agency
  • Technology, Methods and Infrastructure for Networked Medical Research
  • Inserm Toulouse